Hormonal
Subcutaneous semaglutide 2.4 mg administered once weekly, combined with lifestyle interventions, produces sustained, clinically significant weight loss (average 14.9% reduction from baseline) in adults with obesity or overweight.
If you have obesity or are overweight, a once-weekly injection of semaglutide (2.4 mg) combined with lifestyle changes can lead to significant, sustained weight loss, averaging nearly 15% of your body weight. While you may experience mild, temporary nausea, the weekly schedule is designed to improve adherence compared to daily treatments. This option is particularly relevant if other GLP-1 agonists like liraglutide have not provided sufficient results.
Results showed that among obese or overweight participants, semaglutide 2.4 mg once a week plus lifestyle interventions correlated with sustained, clinically significant weight loss... In all randomized patients, the semaglutide 2.4 mg treatment group lost 14.9% from the average baseline weight of 105.3 kg, whereas the placebo group lost 2.4%.
Why this rating
Based on a large, double-blind, randomized controlled trial (Wilding et al., N=1961) cited as a key piece of evidence.
Source
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
Yalin Liu et al. · Frontiers of Medicine · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →